Show simple item record

dc.contributor.authorStein, Evan A.
dc.contributor.authorStrutt, Kristina
dc.contributor.authorSouthworth, Harry
dc.contributor.authorDiggle, Peter J.
dc.contributor.authorMiller, Elinor
dc.contributor.authorHamilton-Craig, Ian R.
dc.contributor.authoret al.
dc.date.accessioned2018-07-31T04:19:23Z
dc.date.available2018-07-31T04:19:23Z
dc.date.issued2003
dc.identifier.issn00029149
dc.identifier.doi10.1016/j.amjcard.2003.08.009
dc.identifier.urihttp://hdl.handle.net/10072/32082
dc.description.abstractHeterozygous familial hypercholesterolemia (HFH) is a common genetic disorder that confers a significantly increased risk of early coronary artery disease. This study compared atorvastatin and rosuvastatin in reducing low-density lipoprotein (LDL) cholesterol in HFH in a global, 18-week, weighted-randomization, double-blind, parallel-group, forced-titration study. Following a 6-week diet lead-in, 623 patients were randomized to 20 mg/day of atorvastatin (n = 187) or rosuvastatin (n = 436) with forced titration at 6-week intervals to 80 mg/day. The primary end point was percentage change in LDL cholesterol from baseline to week 18. At week 18, rosuvastatin therapy produced a significantly greater reduction in LDL cholesterol than atorvastatin (−57.9% vs −50.4%; p <0.001) and a significantly greater increase in high-density lipoprotein (HDL) cholesterol (12.4% vs 2.9%; p <0.001). Rosuvastatin also produced significantly greater reductions in apolipoprotein-B and all 4 major lipid ratios, as well as a significantly greater increases in apolipoprotein A-I (all p <0.001). More patients with HFH with coronary artery disease achieved the National Cholesterol Education Program Adult Treatment Panel III goal of LDL cholesterol <100 mg/dl (<2.6 mmol/L) on rosuvastatin 40 and 80 mg than atorvastatin 80 mg (17%, 24%, and 4.5%, respectively). High-sensitivity C-reactive protein median values were reduced by 33% to 34% in both the 80-mg rosuvastatin- and atorvastatin-treated groups. Both treatments were well tolerated. Thus, in HFH, rosuvastatin force titrated from 20 to 80 mg/day produced significantly greater reductions than atorvastatin 20 to 80 mg/day in LDL cholesterol and improvements in HDL cholesterol and other lipid parameters, and enabled more patients to achieve LDL cholesterol goals.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherExcerpta Medica, Inc.
dc.publisher.placeUnited States
dc.relation.ispartofpagefrom1287
dc.relation.ispartofpageto1293
dc.relation.ispartofissue11
dc.relation.ispartofjournalThe American Journal of Cardiology
dc.relation.ispartofvolume92
dc.subject.fieldofresearchCardiorespiratory Medicine and Haematology
dc.subject.fieldofresearchcode1102
dc.titleComparison of Rosuvastatin Versus Atorvastatin in Patients With Heterozygous Familial Hypercholesterolemia
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2014-10-10T01:55:57Z
gro.hasfulltextNo Full Text
gro.griffith.authorHamilton-Craig, Ian


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record